Impact of darolutamide on local symptoms: pre‐planned and post hoc analyses of the <scp>ARAMIS</scp> trial-Reference-Cited by-同舟云学术

Impact of darolutamide on local symptoms: pre‐planned and post hoc analyses of the ARAMIS trial

Published:2022-09-29 Issue:4 Volume:131 Page:452-460
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU International

Author:

Shore Neal D.¹^ORCID,Stenzl Arnulf²^ORCID,Pieczonka Christopher³,Klaassen Zachary⁴,Aronson William J.⁵,Karsh Lawrence⁶,Ryan Charles J.⁷,Ortiz Jorge⁸,Srinivasan Shankar⁸,Mohamed Ateesha F.⁸,Verholen Frank⁹

Affiliation:

1. Carolina Urologic Research Center Atlantic Urology Clinics Myrtle Beach SC USA

2. Clinic for Urology Tübingen Tübingen Germany

3. Associated Medical Professionals Syracuse NY USA

4. Georgia Cancer Center Augusta GA USA

5. University of California and VA Medical Center Greater Los Angeles Healthcare System Los Angeles CA USA

6. The Urology Center of Colorado Denver CO USA

7. University of Minnesota Minneapolis MN USA

8. Bayer Healthcare Whippany NJ USA

9. Bayer Consumer Care AG Basel Switzerland

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15887

Reference16 articles.

1. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors

2. Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings

3. Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer

4. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer

5. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physician preferences for nonmetastatic castration-resistant prostate cancer treatment in China;Frontiers in Oncology;2024-05-21

2. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS;The Oncologist;2024-02-23

3. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial;European Journal of Cancer;2023-10